Subclavian artery revascularization with subclavian-carotid transposition for TEVAR and non-TEVAR patients.

IF 1.4 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
Journal of Cardiovascular Surgery Pub Date : 2024-04-01 Epub Date: 2023-05-10 DOI:10.23736/S0021-9509.23.11473-X
Francesco Stilo, Vincenzo Catanese, Nunzio Montelione, Antonio Nenna, Fabio Pilato, Teresa Gabellini, Massimo Chello, Vincenzo DI Lazzaro, Francesco Spinelli
{"title":"Subclavian artery revascularization with subclavian-carotid transposition for TEVAR and non-TEVAR patients.","authors":"Francesco Stilo, Vincenzo Catanese, Nunzio Montelione, Antonio Nenna, Fabio Pilato, Teresa Gabellini, Massimo Chello, Vincenzo DI Lazzaro, Francesco Spinelli","doi":"10.23736/S0021-9509.23.11473-X","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Subclavian artery revascularization (SAR) has become an increasingly performed technique in patients undergoing thoracic endovascular aortic aneurysm repair (TEVAR), in order to optimize the proximal landing zone, or in patients with significant atherosclerotic diseases. SAR was usually achieved through carotid-subclavian bypass (CSB) which is daunted by graft and patency-related issues, or through subclavian carotid transposition (SCT) which has recently been reconsidered as a potential solution. Nowadays, multiple endovascular strategies including parallel grafts, chimney graft and branch-fenestrated repair, are available in patients unfit for open SAR. However, there is no consensus on the preferable technique in both TEVAR- and non TEVAR-patients. The purpose of this study was to evaluate our experience with SCT in terms of overall postoperative adverse events and mid-term patency rate.</p><p><strong>Methods: </strong>We performed a retrospective cohort study, including all patients who underwent SCT between June 2014 and March 2020 at our Division. Preoperative risk factors, symptoms, intraoperative details, postoperative outcomes and follow-up data were collected.</p><p><strong>Results: </strong>A total of 27 patients were included in this study. Indications for SCT included aortic arch debranching for TEVAR for thoracic aortic aneurysm and type B dissection and symptomatic subclavian steal syndrome (SSS). There were no major perioperative adverse events or major neurological complications; five minor adverse events occurred (18.5%) (3 Horner' Syndrome, 1 hematoma requiring reoperation,1 pneumothorax). Peripheral nerve injuries and lymphatic lesions were not recorded. On a mean follow-up of 21±16 months, SCT patency was confirmed in all patients and no deaths occurred. Comparison of baseline and operative characteristics and intraoperative details between groups of patients with or without adverse events did not found differences.</p><p><strong>Conclusions: </strong>SCT should be considered a feasible, effective and safe technique for SAR, with low perioperative complications and optimal mid-term patency. This surgical technique appears to provide a lower risk of neurological events and mortality, particularly in TEVAR patients, reducing the complications caused by the coverage of the left subclavian artery.</p>","PeriodicalId":50245,"journal":{"name":"Journal of Cardiovascular Surgery","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cardiovascular Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.23736/S0021-9509.23.11473-X","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/5/10 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Subclavian artery revascularization (SAR) has become an increasingly performed technique in patients undergoing thoracic endovascular aortic aneurysm repair (TEVAR), in order to optimize the proximal landing zone, or in patients with significant atherosclerotic diseases. SAR was usually achieved through carotid-subclavian bypass (CSB) which is daunted by graft and patency-related issues, or through subclavian carotid transposition (SCT) which has recently been reconsidered as a potential solution. Nowadays, multiple endovascular strategies including parallel grafts, chimney graft and branch-fenestrated repair, are available in patients unfit for open SAR. However, there is no consensus on the preferable technique in both TEVAR- and non TEVAR-patients. The purpose of this study was to evaluate our experience with SCT in terms of overall postoperative adverse events and mid-term patency rate.

Methods: We performed a retrospective cohort study, including all patients who underwent SCT between June 2014 and March 2020 at our Division. Preoperative risk factors, symptoms, intraoperative details, postoperative outcomes and follow-up data were collected.

Results: A total of 27 patients were included in this study. Indications for SCT included aortic arch debranching for TEVAR for thoracic aortic aneurysm and type B dissection and symptomatic subclavian steal syndrome (SSS). There were no major perioperative adverse events or major neurological complications; five minor adverse events occurred (18.5%) (3 Horner' Syndrome, 1 hematoma requiring reoperation,1 pneumothorax). Peripheral nerve injuries and lymphatic lesions were not recorded. On a mean follow-up of 21±16 months, SCT patency was confirmed in all patients and no deaths occurred. Comparison of baseline and operative characteristics and intraoperative details between groups of patients with or without adverse events did not found differences.

Conclusions: SCT should be considered a feasible, effective and safe technique for SAR, with low perioperative complications and optimal mid-term patency. This surgical technique appears to provide a lower risk of neurological events and mortality, particularly in TEVAR patients, reducing the complications caused by the coverage of the left subclavian artery.

为 TEVAR 和非 TEVAR 患者进行锁骨下动脉再通术与锁骨下-颈动脉转位术。
背景:为了优化近端着床区,或对患有严重动脉粥样硬化疾病的患者进行胸腔内血管主动脉瘤修补术(TEVAR),锁骨下动脉血管重建(SAR)已成为越来越多患者采用的技术。SAR通常是通过颈动脉-锁骨下旁路(CSB)或锁骨下颈动脉转位(SCT)来实现的,前者因移植物和通畅问题而令人望而却步,后者最近作为一种潜在的解决方案被重新考虑。如今,对于不适合开放式 SAR 的患者,可以采用多种血管内策略,包括平行移植物、烟囱移植物和分支瓣膜修复术。然而,对于 TEVAR 和非 TEVAR 患者而言,哪种技术更可取尚未达成共识。本研究旨在从术后总体不良事件和中期通畅率方面评估我们使用 SCT 的经验:我们进行了一项回顾性队列研究,包括 2014 年 6 月至 2020 年 3 月期间在我科接受 SCT 的所有患者。收集术前风险因素、症状、术中细节、术后结果和随访数据:本研究共纳入 27 名患者。SCT的适应症包括为胸主动脉瘤、B型夹层和无症状锁骨下盗血综合征(SSS)的TEVAR进行主动脉弓去支术。围手术期未发生重大不良事件或重大神经系统并发症;发生了5起轻微不良事件(18.5%)(3起霍纳综合征、1起血肿需要再次手术、1起气胸)。外周神经损伤和淋巴损伤没有记录。在平均 21±16 个月的随访中,所有患者的 SCT 均被证实通畅,无死亡病例。比较有或无不良事件患者组的基线和手术特征以及术中细节,未发现差异:SCT应被视为一种可行、有效和安全的SAR技术,围手术期并发症少,中期通畅率最佳。这种手术技术似乎降低了神经系统事件和死亡率的风险,尤其是在TEVAR患者中,减少了左锁骨下动脉覆盖引起的并发症。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.50
自引率
7.10%
发文量
204
审稿时长
4-8 weeks
期刊介绍: The Journal of Cardiovascular Surgery publishes scientific papers on cardiac, thoracic and vascular surgery. Manuscripts may be submitted in the form of editorials, original articles, review articles, case reports, therapeutical notes, special articles and letters to the Editor. Manuscripts are expected to comply with the instructions to authors which conform to the Uniform Requirements for Manuscripts Submitted to Biomedical Editors by the International Committee of Medical Journal Editors (www.icmje.org). Articles not conforming to international standards will not be considered for acceptance.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信